EUVIMEDEUVIMED entdecken
Fallbericht

Adnexotropic and granulomatous mycosis fungoides following TNF ‐α inhibitor treatment

Hayden Doughty, Andrew Scripture, Joi B Carter, Aravindhan Sriharan, Shaofeng Yan iD, Frederick Lansigan, Shabnam Momtahen iD

Journal of Cutaneous Pathology · 2023

DOI: 10.1111/cup.14441 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Journal of Cutaneous Pathology, 2023. Verfasst von Hayden Doughty und 6 weiteren Autor:innen. Beteiligte Einrichtung: Dartmouth Geisel School of Medicine, Hanover, New Hampshire, USA. Hauptthemen laut MEDLINE: Mycosis Fungoides, Lymphoma, T-Cell, Cutaneous, Skin Neoplasms, Psoriasis. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 9 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Recent publications have documented an increased prevalence of cutaneous T‐cell lymphoma (CTCL) in patients undergoing tumor necrosis factor alpha (TNF‐α) inhibitor therapy. Herein, we present an uncommon manifestation of mycosis fungoides (MF) with unique pathological findings after the initiation of adalimumab therapy for the treatment of psoriasis. One year after starting treatment, the patient noticed a slowly growing, eroded plaque on the left cheek, the biopsy of which demonstrated mixed granulomatous and adnexotropic lymphocytic infiltrate with features characteristics of MF. In the following months, the patient developed pink‐ and violet‐colored scaly plaques on the right posterior upper arm and right medial upper arm. Biopsy of these plaques also revealed findings compatible with MF. T‐cell receptor (TCR) clonality studies by PCR revealed identical T‐cell clones in the samples obtained from the cheek, right posterior upper arm, and right medial upper arm. TCR clonality studies of a long‐standing psoriatic plaque on the right thigh failed to reveal similar T‐cell clones. Blurring of histopathologic presentation by TNF‐α inhibitors could greatly complicate the identification of MF subtypes. Providers treating patients with TNF‐α inhibitors must be aware of the risk of cutaneous lymphoma development and the potential deviations from their expected presentations. In patients without an initial biopsy, the possibility of pre‐existing CTCL with psoriasiform presentation should be considered.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Mycosis FungoidesLymphoma, T-Cell, CutaneousSkin NeoplasmsPsoriasisHumansTumor Necrosis Factor-alphaReceptors, Antigen, T-Cell

Stichwörter der Autor:innen

TNF-α inhibitoradnexotropic mycosis fungoidescutaneous T-cell lymphomagranulomatous mycosis fungoidesmycosis fungoides

Substanzen

Tumor Necrosis Factor-alphaReceptors, Antigen, T-Cell

Autor:innen und Institutionen

  • Dartmouth Geisel School of Medicine, Hanover, New Hampshire, USA.
  • Department of Dermatology, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, USA.
  • Department of Pathology and Laboratory Medicine, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, USA.
  • Department of Hematology and Oncology, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, USA.

ORCID-Profile: Shaofeng Yan, Shabnam Momtahen

Zitieren

APA

Doughty, H., Scripture, A., Carter, J. B., Sriharan, A., Yan, S., Lansigan, F., & Momtahen, S. (2023). Adnexotropic and granulomatous mycosis fungoides following TNF ‐α inhibitor treatment. Journal of Cutaneous Pathology. https://doi.org/10.1111/cup.14441

Vancouver

Doughty H, Scripture A, Carter JB, Sriharan A, Yan S, Lansigan F, et al. Adnexotropic and granulomatous mycosis fungoides following TNF ‐α inhibitor treatment. Journal of Cutaneous Pathology. 2023. doi:10.1111/cup.14441

BibTeX
@article{Doughty2023,
  author = {Doughty, Hayden and Scripture, Andrew and Carter, Joi B and Sriharan, Aravindhan and Yan, Shaofeng and Lansigan, Frederick and Momtahen, Shabnam},
  title = {Adnexotropic and granulomatous mycosis fungoides following TNF ‐α inhibitor treatment},
  journal = {Journal of Cutaneous Pathology},
  year = {2023},
  doi = {10.1111/cup.14441}
}
Kostenlos starten →